Oral HIV-associated Kaposi sarcoma.
Identifieur interne : 002097 ( PubMed/Curation ); précédent : 002096; suivant : 002098Oral HIV-associated Kaposi sarcoma.
Auteurs : L. Pantanowitz [États-Unis] ; R A G. Khammissa ; J. Lemmer ; L. FellerSource :
- Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology [ 1600-0714 ] ; 2013.
Descripteurs français
- KwdFr :
- Antirétroviraux (usage thérapeutique), Herpèsvirus humain de type 8 (physiologie), Humains, Infections opportunistes liées au SIDA (anatomopathologie), Infections opportunistes liées au SIDA (traitement médicamenteux), Infections à VIH (anatomopathologie), Lymphoedème (anatomopathologie), Sarcome de Kaposi (anatomopathologie), Sarcome de Kaposi (traitement médicamenteux), Thérapie antirétrovirale hautement active, Tumeurs de la bouche (anatomopathologie), Tumeurs de la bouche (traitement médicamenteux).
- MESH :
- anatomopathologie : Infections opportunistes liées au SIDA, Infections à VIH, Lymphoedème, Sarcome de Kaposi, Tumeurs de la bouche.
- physiologie : Herpèsvirus humain de type 8.
- traitement médicamenteux : Infections opportunistes liées au SIDA, Sarcome de Kaposi, Tumeurs de la bouche.
- usage thérapeutique : Antirétroviraux.
- Humains, Thérapie antirétrovirale hautement active.
English descriptors
- KwdEn :
- AIDS-Related Opportunistic Infections (drug therapy), AIDS-Related Opportunistic Infections (pathology), Anti-Retroviral Agents (therapeutic use), Antiretroviral Therapy, Highly Active, HIV Infections (pathology), Herpesvirus 8, Human (physiology), Humans, Lymphedema (pathology), Mouth Neoplasms (drug therapy), Mouth Neoplasms (pathology), Sarcoma, Kaposi (drug therapy), Sarcoma, Kaposi (pathology).
- MESH :
- chemical , therapeutic use : Anti-Retroviral Agents.
- drug therapy : AIDS-Related Opportunistic Infections, Mouth Neoplasms, Sarcoma, Kaposi.
- pathology : AIDS-Related Opportunistic Infections, HIV Infections, Lymphedema, Mouth Neoplasms, Sarcoma, Kaposi.
- physiology : Herpesvirus 8, Human.
- Antiretroviral Therapy, Highly Active, Humans.
Abstract
Kaposi sarcoma (KS), an AIDS defining condition, remains one of the most commonly HIV-associated neoplasms. While the use of highly active antiretroviral therapy (HAART) has brought about a dramatic decrease in the prevalence and incidence of AIDS-KS worldwide, this has not been the case in resource-poor sub-Saharan African countries, where HIV has reached epidemic proportions and human herpesvirus-8 infection is endemic. Oral involvement is a common manifestation of AIDS-associated KS and may be an early presenting finding of HIV infection. The clinical manifestation of oral KS can vary and may have an unpredictable course ranging from mild to fulminant. Rapidly progressive facial lymphoedema associated with extensive advanced oral KS portends a poor prognosis. Oral KS may regress with antiretroviral therapy or may flare up as part of the immune reconstitution inflammatory syndrome. The oral lesions of AIDS-KS are best managed with HAART together with systemic chemotherapy. This article provides a review of contemporary knowledge of the biology, pathology, clinical features and management of oral AIDS-KS.
DOI: 10.1111/j.1600-0714.2012.01180.x
PubMed: 22672182
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002097
Links to Exploration step
pubmed:22672182Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Oral HIV-associated Kaposi sarcoma.</title><author><name sortKey="Pantanowitz, L" sort="Pantanowitz, L" uniqKey="Pantanowitz L" first="L" last="Pantanowitz">L. Pantanowitz</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. pantanowitzl@upmc.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA</wicri:regionArea></affiliation></author><author><name sortKey="Khammissa, R A G" sort="Khammissa, R A G" uniqKey="Khammissa R" first="R A G" last="Khammissa">R A G. Khammissa</name></author><author><name sortKey="Lemmer, J" sort="Lemmer, J" uniqKey="Lemmer J" first="J" last="Lemmer">J. Lemmer</name></author><author><name sortKey="Feller, L" sort="Feller, L" uniqKey="Feller L" first="L" last="Feller">L. Feller</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:22672182</idno><idno type="pmid">22672182</idno><idno type="doi">10.1111/j.1600-0714.2012.01180.x</idno><idno type="wicri:Area/PubMed/Corpus">002097</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002097</idno><idno type="wicri:Area/PubMed/Curation">002097</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002097</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Oral HIV-associated Kaposi sarcoma.</title><author><name sortKey="Pantanowitz, L" sort="Pantanowitz, L" uniqKey="Pantanowitz L" first="L" last="Pantanowitz">L. Pantanowitz</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. pantanowitzl@upmc.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA</wicri:regionArea></affiliation></author><author><name sortKey="Khammissa, R A G" sort="Khammissa, R A G" uniqKey="Khammissa R" first="R A G" last="Khammissa">R A G. Khammissa</name></author><author><name sortKey="Lemmer, J" sort="Lemmer, J" uniqKey="Lemmer J" first="J" last="Lemmer">J. Lemmer</name></author><author><name sortKey="Feller, L" sort="Feller, L" uniqKey="Feller L" first="L" last="Feller">L. Feller</name></author></analytic><series><title level="j">Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology</title><idno type="eISSN">1600-0714</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>AIDS-Related Opportunistic Infections (drug therapy)</term><term>AIDS-Related Opportunistic Infections (pathology)</term><term>Anti-Retroviral Agents (therapeutic use)</term><term>Antiretroviral Therapy, Highly Active</term><term>HIV Infections (pathology)</term><term>Herpesvirus 8, Human (physiology)</term><term>Humans</term><term>Lymphedema (pathology)</term><term>Mouth Neoplasms (drug therapy)</term><term>Mouth Neoplasms (pathology)</term><term>Sarcoma, Kaposi (drug therapy)</term><term>Sarcoma, Kaposi (pathology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antirétroviraux (usage thérapeutique)</term><term>Herpèsvirus humain de type 8 (physiologie)</term><term>Humains</term><term>Infections opportunistes liées au SIDA (anatomopathologie)</term><term>Infections opportunistes liées au SIDA (traitement médicamenteux)</term><term>Infections à VIH (anatomopathologie)</term><term>Lymphoedème (anatomopathologie)</term><term>Sarcome de Kaposi (anatomopathologie)</term><term>Sarcome de Kaposi (traitement médicamenteux)</term><term>Thérapie antirétrovirale hautement active</term><term>Tumeurs de la bouche (anatomopathologie)</term><term>Tumeurs de la bouche (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Retroviral Agents</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Infections opportunistes liées au SIDA</term><term>Infections à VIH</term><term>Lymphoedème</term><term>Sarcome de Kaposi</term><term>Tumeurs de la bouche</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>AIDS-Related Opportunistic Infections</term><term>Mouth Neoplasms</term><term>Sarcoma, Kaposi</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>AIDS-Related Opportunistic Infections</term><term>HIV Infections</term><term>Lymphedema</term><term>Mouth Neoplasms</term><term>Sarcoma, Kaposi</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Herpèsvirus humain de type 8</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Herpesvirus 8, Human</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections opportunistes liées au SIDA</term><term>Sarcome de Kaposi</term><term>Tumeurs de la bouche</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antirétroviraux</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Antiretroviral Therapy, Highly Active</term><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Thérapie antirétrovirale hautement active</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Kaposi sarcoma (KS), an AIDS defining condition, remains one of the most commonly HIV-associated neoplasms. While the use of highly active antiretroviral therapy (HAART) has brought about a dramatic decrease in the prevalence and incidence of AIDS-KS worldwide, this has not been the case in resource-poor sub-Saharan African countries, where HIV has reached epidemic proportions and human herpesvirus-8 infection is endemic. Oral involvement is a common manifestation of AIDS-associated KS and may be an early presenting finding of HIV infection. The clinical manifestation of oral KS can vary and may have an unpredictable course ranging from mild to fulminant. Rapidly progressive facial lymphoedema associated with extensive advanced oral KS portends a poor prognosis. Oral KS may regress with antiretroviral therapy or may flare up as part of the immune reconstitution inflammatory syndrome. The oral lesions of AIDS-KS are best managed with HAART together with systemic chemotherapy. This article provides a review of contemporary knowledge of the biology, pathology, clinical features and management of oral AIDS-KS.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22672182</PMID><DateCreated><Year>2013</Year><Month>03</Month><Day>05</Day></DateCreated><DateCompleted><Year>2013</Year><Month>09</Month><Day>19</Day></DateCompleted><DateRevised><Year>2013</Year><Month>03</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1600-0714</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>3</Issue><PubDate><Year>2013</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology</Title><ISOAbbreviation>J. Oral Pathol. Med.</ISOAbbreviation></Journal><ArticleTitle>Oral HIV-associated Kaposi sarcoma.</ArticleTitle><Pagination><MedlinePgn>201-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1600-0714.2012.01180.x</ELocationID><Abstract><AbstractText>Kaposi sarcoma (KS), an AIDS defining condition, remains one of the most commonly HIV-associated neoplasms. While the use of highly active antiretroviral therapy (HAART) has brought about a dramatic decrease in the prevalence and incidence of AIDS-KS worldwide, this has not been the case in resource-poor sub-Saharan African countries, where HIV has reached epidemic proportions and human herpesvirus-8 infection is endemic. Oral involvement is a common manifestation of AIDS-associated KS and may be an early presenting finding of HIV infection. The clinical manifestation of oral KS can vary and may have an unpredictable course ranging from mild to fulminant. Rapidly progressive facial lymphoedema associated with extensive advanced oral KS portends a poor prognosis. Oral KS may regress with antiretroviral therapy or may flare up as part of the immune reconstitution inflammatory syndrome. The oral lesions of AIDS-KS are best managed with HAART together with systemic chemotherapy. This article provides a review of contemporary knowledge of the biology, pathology, clinical features and management of oral AIDS-KS.</AbstractText><CopyrightInformation>© 2012 John Wiley & Sons A/S.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pantanowitz</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. pantanowitzl@upmc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khammissa</LastName><ForeName>R A G</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Lemmer</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Feller</LastName><ForeName>L</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>06</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>J Oral Pathol Med</MedlineTA><NlmUniqueID>8911934</NlmUniqueID><ISSNLinking>0904-2512</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D044966">Anti-Retroviral Agents</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C554498">AIDS-related Kaposi sarcoma</SupplMeshName></SupplMeshList><CitationSubset>D</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017088" MajorTopicYN="N">AIDS-Related Opportunistic Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044966" MajorTopicYN="N">Anti-Retroviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D023241" MajorTopicYN="N">Antiretroviral Therapy, Highly Active</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019288" MajorTopicYN="N">Herpesvirus 8, Human</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008209" MajorTopicYN="N">Lymphedema</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009062" MajorTopicYN="N">Mouth Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012514" MajorTopicYN="N">Sarcoma, Kaposi</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>6</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>6</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22672182</ArticleId><ArticleId IdType="doi">10.1111/j.1600-0714.2012.01180.x</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002097 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002097 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:22672182
|texte= Oral HIV-associated Kaposi sarcoma.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:22672182" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |